Fosun sees stellar H1 expansion

Source: Xinhua | 2017-08-31

FOSUN Pharma Group turned in strong double-digit growth in revenue and profit as well as overseas income in the first half of the year, the Chinese pharmaceutical company said yesterday.

The company posted a 20.4 percent jump in revenue to 8.35 billion yuan (US$1.24 billion) while profit added 12.6 percent from a year ago to 1.69 billion yuan. Income from overseas surged 58.6 percent annually to 1.47 billion yuan amid its successful global strategy.

In the first six months, revenue from pharmaceutical manufacturing and research and development totaled 5.77 billion yuan, up 19.12 percent annually while that of its healthcare business gained 37 percent from a year ago to 1.01 billion yuan.

The group said it spent 626 million yuan on research and development in the first half, up 28 percent from the same period a year ago.